<\/p>\n
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near multi-year lows. <\/p>\n
So when Goldman Sachs steps up with a price target hike to $250, it’s worth asking what the bank is actually seeing.<\/p>\n
The short answer: Leqembi, Biogen’s Alzheimer’s treatment, is delivering. And the case for the stock goes beyond today’s sales figures, hinging on what the next 18 months could look like if several catalysts land on schedule.<\/p>\n
Goldman’s analyst Salveen Richter raised the bank’s price target on BIIB from $238 to $250, keeping a buy rating intact, according to MarketScreener.<\/p>\n
The move followed a Q1 2026 earnings report that comfortably beat expectations, topped off by encouraging signals from Biogen’s experimental next-generation Alzheimer’s drug.<\/p>\n
Goldman’s $250 target reflects more than one drug doing well<\/p>\n
Goldman didn’t raise its target on blind optimism. The Biogen Q1 2026 earnings report gave the bank real data to work with.<\/p>\n
Biogen posted Q1 revenue of $2.48 billion, up 2% year over year, and non-GAAP earnings per share of $3.57, well ahead of the $2.95 consensus estimate.<\/p>\n
According to the Q1 2026 earnings transcript, Leqembi generated $168 million in global in-market sales during the quarter, a 74% jump from the same period a year ago.<\/p>\n
That 74% growth rate is the kind of number that gets a bank’s attention. Leqembi is still early in its commercial ramp, which means the growth curve has room to steepen if a few structural hurdles clear.<\/p>\n
Goldman’s Salveen Richter pressed management on the Q1 earnings call about blood-based biomarker adoption, a key factor in whether Leqembi can reach more patients faster. <\/p>\n
The short version: Adoption is accelerating, particularly through Biogen’s primary care pilot program, which is showing higher biomarker usage rates among enrolled physicians.<\/p>\n
That matters because diagnosing Alzheimer’s at earlier stages opens up a larger pool of eligible patients for treatment.<\/p>\n
Biogen’s Alzheimer’s drug Leqembi is reshaping Wall Street’s outlook for the Cambridge-based biotech’s long-term growth story.<\/p>\n
Photo by Boston Globe on Getty Images<\/p>\n
What Leqembi’s commercial momentum actually signals<\/p>\n
Leqembi is an FDA-approved therapy for early Alzheimer’s disease that works by removing amyloid plaques from the brain, Reuters noted.<\/p>\n
Amyloid is a protein that builds up abnormally in Alzheimer’s patients and is widely believed to contribute to cognitive decline.<\/p>\n
Leqembi holds 65% to 70% market share on a patient-number basis over Eli Lilly’s competing drug Kisunla, according to Eisai’s most recent guidance, Investing.com confirmed.<\/p>\n
That’s a meaningful lead in a market that is still small but widely expected to grow substantially as awareness, diagnostics, and reimbursement infrastructure improve.<\/p>\n
Related: Goldman Sachs doubles down on stock market message for 2026<\/p>\n
A key near-term catalyst for Leqembi’s growth, Practical Neurology confirms, is the FDA’s Aug. 24 PDUFA decision date for IQLIK, a subcutaneous (under-the-skin autoinjector) formulation of Leqembi. This matters for a practical reason.<\/p>\n
Currently, patients receive Leqembi via an intravenous drip at a clinic, every two weeks. <\/p>\n
The subcutaneous version would allow once-weekly home dosing in roughly 15 seconds. Patient convenience alone could meaningfully improve retention and access, especially in markets where infusion centers are not widely available.<\/p>\n
Here’s what Biogen’s Leqembi growth story depends on:FDA approval of IQLIK’s induction subcutaneous formulation by the August 24 PDUFA date Full Medicare Part D coverage kicking in as of January 2027, which would remove the biggest cost barrier for U.S. seniors Continued expansion of blood-based biomarker testing, which lets primary care doctors screen patients earlier and more easily International approvals in Japan and China for the subcutaneous formulation, which would add a second growth leg outside the U.S.The experimental drug that quietly added fuel to Goldman’s call<\/p>\n
Alongside the Q1 earnings beat, Biogen dropped another significant piece of news that drew less attention than it deserved.<\/p>\n
On May 14, 2026, Biogen’s investor relations page shared topline results from the Phase 2 CELIA study for diranersen (BIIB080), an experimental drug designed to reduce tau protein in the brain.<\/p>\n
Unlike Leqembi, which targets amyloid, diranersen goes after tau, a second protein associated with Alzheimer’s progression.<\/p>\n
Biogen described the CELIA results as “the first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease.” <\/p>\n
Related: Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market<\/p>\n
The trial did not hit its primary dose-response endpoint, which is a specific statistical hurdle, but Biogen revealed it plans to advance diranersen to registrational development anyway, based on the broader signals the trial produced.<\/p>\n
Ionis Pharmaceuticals, which developed the drug and licensed it to Biogen, separately confirmed that decision.<\/p>\n
This is meaningful context for the Goldman target raise. <\/p>\n
If diranersen reaches approval in the years ahead, Biogen would have two distinct mechanisms targeting Alzheimer’s, giving it potentially the deepest clinical footprint in a disease category that affects more than 6 million Americans, according to the Alzheimer’s Association.<\/p>\n
How BIIB has performed compared to the broader market<\/p>\n
It helps to put the stock’s recent trajectory in concrete terms. Here’s a look at BIIB versus the S&P 500’s recent performance snapshot.<\/p>\n
Period<\/p>\n
BIIB<\/p>\n
S&P 500<\/p>\n
1 week<\/p>\n
+6.59% (pre-market, May 14)<\/p>\n
+0.58%<\/p>\n
1 month<\/p>\n
Recovering from $184 lows<\/p>\n
Broadly flat<\/p>\n
YTD<\/p>\n
Up from 52-week low of ~$119<\/p>\n
Moderate gains<\/p>\n
52-week range<\/p>\n
$119.18 \u2013 $205.97<\/p>\n
$5,767.41 – $7,517.12<\/p>\n
Source: Yahoo Finance S&P 500 || Yahoo Finance BIIB<\/p>\n
The stock’s 52-week run from $119 to nearly $206 reflects a substantial re-rating, with most of the gains coming as Leqembi’s commercial performance improved and multiple analysts lifted price targets. <\/p>\n
Yet even at current levels, Biogen trades at a forward price-to-earnings ratio that remains well below large-cap biotech peers.<\/p>\n
UBS, which upgraded BIIB to buy with a $225 target in late April 2026, according to 24\/7 Wall St, noted the stock trades at roughly 13x forward earnings, a meaningful discount to the sector. Guggenheim has a $260 price target on BIIB, also with a buy rating, StreetInsider reported.<\/p>\n
That gives investors a rough range of where the bull case sits: somewhere between Goldman’s $250 and Guggenheim’s $260, depending on how the pipeline delivers.<\/p>\n
What still needs to happen before BIIB can hit $250<\/p>\n
Goldman’s $250 target is not a given. There are real conditions that need to fall into place.<\/p>\n
The risks worth keeping in mind:<\/p>\n
Biogen’s total revenue is still expected to decline by a mid-single-digit percentage in 2026, driven by continued erosion in its older multiple sclerosis drugs.The company trimmed its full-year 2026 non-GAAP EPS guidance to $14.25 to $15.25, partly due to charges from acquisitions, including the planned $5.6 billion deal to buy Apellis Pharmaceuticals.The IQLIK FDA decision on August 24 is binary. An approval would likely push the stock higher; a setback or a complete response letter could reverse recent gains quickly.Diranersen’s path from Phase 2 to approval is long, likely taking several years, and Phase 3 trials regularly fail, even when Phase 2 data look promising.<\/p>\n
The Apellis acquisition deserves attention here. <\/p>\n
Biogen struck a deal to buy Apellis for roughly $5.6 billion, adding two approved drugs in immunology and rare kidney disease (Empaveli and Syfovre) and strengthening the case for felzartamab, its Phase 3 kidney-disease candidate. <\/p>\n
That deal will add leverage and pressure-free cash flow in the near term, with management forecasting full debt repayment by the end of 2027.<\/p>\n
Key takeaways for investors on Biogen stock<\/p>\n
Goldman Sachs’ $250 target reflects real commercial momentum: Leqembi growing 74% year-over-year, market leadership over Eli Lilly’s Kisunla, and a next-generation drug producing the first clinical evidence of tau reduction and cognitive benefit.<\/p>\n
The bear case is equally real. Overall revenue is still declining, the Apellis acquisition loads the balance sheet, and the MS franchise keeps shrinking, Grandview Research notes.<\/p>\n
The question for investors is whether Leqembi’s growth curve becomes large enough, fast enough, to carry the weight.<\/p>\n
The $250 target implies roughly 15-20% upside from recent trading levels, but getting there requires Leqembi’s momentum to hold, IQLIK to clear its August 24 FDA hurdle, and the Alzheimer’s market to keep expanding. <\/p>\n
Long-term investors who believe in that trajectory will find Biogen’s current valuation compelling. <\/p>\n
Those who need steadier fundamentals may want to wait for the IQLIK decision before adding exposure.<\/p>\n
Related: Fidelity on selling stocks this May<\/p>\n
#Goldman #Sachs #sets #Biogen #stock #price #target #bold #Alzheimer039s #bet<\/p>\n","protected":false},"excerpt":{"rendered":"
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[12294,157,12293,2602,1305,100,1306,480,91,336],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/6553"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6553"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/6553\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}